Journal
DERMATOLOGIC CLINICS
Volume 21, Issue 2, Pages 311-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/S0733-8635(02)00093-1
Keywords
-
Categories
Ask authors/readers for more resources
Acyclovir and related compounds are the mainstay of therapy of infections that are caused by human herpesvirus types 1, 11, and III. Resistance to this class of drugs has increased among patients who are immunocompromised (bone marrow and organ transplant patients, patients with cancer, and patients infected with HIV), leading to persistent mucocutaneous lesions or serious systemic infections. Alternative treatment regimens include parenteral foscarnet, vidarabine, and cidofovir, as well as topical foscarnet, cidofovir, trifluridine, and imiquimod. Ribonucleotide reductase inhibitors offer considerable promise for future treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available